// App-Quantinova.ai

OP0023 : SARILUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: RESULTS OF A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL STUDY

Researchers

Presenter

  • T.W. Huizinga

Principal Investigators

  • A.J. Kivitz

  • M. Rell-Bakalarska

  • R.M. Fleischmann

  • M. Jasson

  • A.R. Radin

  • M.C. Genovese

Medical Centers

  • Department of Urology, Leiden Unviersity Medical Center, Leiden, Netherlands

  • Immunology & Rheumatology, Stanford University Medical Center, Palo Alto, United States

  • Rheumatology and Osteoporosis Outpatient Clinic, Warsaw, Poland

  • Metroplex Clinical Research Center, Dallas, United States

  • Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, United States

Locations

  • United States

  • Poland

  • Netherlands

Companies

  • Regeneron Pharmaceut

  • Sanofi S.A.

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Acute lung injury

  • Rheumatoid arthritis

  • Neutropenia

  • Inflammatory Arthritis

  • Stroke

Biomarkers

  • Alanine transaminase

  • High sensitivity C-reactive protein

  • Interleukin 6

  • Albumin/creatinine

Drug/Treatment

  • Methotrexate

  • Sarilumab

  • Ranitidine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved